AbbVie has ended speculation about what it will charge for its newly-approved Vuity therapy for presbyopia, a sight condition characterised by difficulty in focusing on near objects.
With drug pricing controls back on the legislative table in the US, the influential Institute for Clinical and Economic Review (ICER) has published its third report on "unsupported" price i
The development of digital medicine requires valid endpoints that can be used in clinical trials, and a consortium of pharma companies has just identified a new one for atopic dermatitis.
The FDA has approved the first and so far only pharmacological treatment for presbyopia, a sight condition that typically starts in middle age and involves difficulty in focusing on near ob
AbbVie has reported that a subcutaneous infusion of Parkinson's disease candidate ABBV-951 was more effective than standard oral therapy in a phase 3 trial, paving the way for regulatory fi
Biosimilar competition to AbbVie's big-selling Humira drug in the US has just been ratcheted up by the FDA approval of Boehringer Ingelheim's Cyltezo – which can be substituted for the refe
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.